Loss of cell cycle control allows selective microtubule-active drug- induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3425-3428

  Blagosklonny, Mikhail V ^a,b   Bishop, Philippe C ^a   Robey, Robert ^a   Fojo, Tito ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR; PACLITAXEL; PROTEIN BCL 2; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL IMMORTALIZATION; CELL PROTECTION; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FEMALE; HL-60 CELLS; HUMANS; MICROTUBULES; MITOSIS; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TETRADECANOYLPHORBOL ACETATE; TUBULIN; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0034235610     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1014, 1995.
2. Horwitz, S. B. Mechanism of action of taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
3. Jordan, M. A., and Wilson, L. Microtubules and aclin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol., 10: 123-130, 1998.
4. Blagosklonny, M. V., and Fojo, T. Molecular effects of paclitaxel: myths and reality. Int. J. Cancer, 83: 151-156, 1999.
5. Pardee, A. B. A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. USA, 71: 1286-1290, 1974.
6. Pardee, A. B., and James, L. J. Selective killing of transformed baby hamster kidney (BHK) cells. Proc. Natl. Acad. Sci. USA, 72: 4994-4998, 1975.
7. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1999.
8. Blagosklonny, M. V. A node between apoptosis, proliferation and growth arrest. BioEssays, 21: 704-709, 1999.
9. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
10. Blagosklonny, M. V., Chuman, Y., Bergan, R. C., and Fojo, T. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia, 13: 1028-1036, 1999.
11. Reed, J. C. Double identity for proteins of the Bcl-2 family. Nature, 773-776, 1997.
12. Haldar, S., Jena, N., and Croce, C. M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4507-4511, 1995.
13. Yamamoto, K., Ichijo, H., and Korsmeyer, S. J. BCL-2 is phosphorylated and inactivated by ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol. Cell. Biol., 19: 8469-8478, 1999.
14. Blagosklonny, M. V., Giannakakou, P., El-Deiry, W. S., Kingston, D. G. I., Higgs, P. I., Neckers, L., and Fojo, T. Raf1/bcl2 phosphorylation: a step from microtubule damage to cell death. Cancer Res., 57: 130-135, 1997.
15. Haldar, S., Basu, A., and Croce, C. M. Bcl2 is the guardian of microtubule integrity. Cancer Res., 57: 229-233, 1997.
16. Ling, Y. H., Tornos, C., and Perez-Soler, R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem., 273: 18984-18991, 1998.
17. Bhalla, K., Ibrado, A. M., Tourkina, E., Tang, C., Maloney, M. E., and Huang, Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia, 7: 563-568, 1993.
18. Solary, E., Bertrand, R., Kohn, K. W., and Pommier, Y. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood, 81: 1359-1368, 1993.
19. Sordet, O., Bettaieb, A., Bruey, J. M., Eymin, B., Droin, N., Ivarsson, M., Garrido, C., and Solary, E. Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. Cell Death Differ, 6: 351-361, 1999.
20. Huang, Y., Sheikh, M. S., Fornace, A. J. J., and Holbrook, N. J. Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene, 18: 3431-3439, 1999.
21. Lieu, C. H., Liu, C. C., Yu, T. H., Chen, K. D., Chang, Y. N., and Lai, Y. K. Role of mitogen-activated protein kinase in Taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ., 9: 767-776, 1998.
22. Asada, M., Yamada, T., Ichijo, H., Delia, D., Miyazono, K., Fukumuro, K., and Mizutani, S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J., 18: 1223-1234, 1999.
23. Torres, K., and Horwitz, S. B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res., 58: 3620-3626, 1998.
24. Grem, J. L., Nguyen, D., Monahan, B. P., Kao, V., and Geoffroy, F. J. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem. Pharmacol., 58: 477-486, 1999.
25. Blagosklonny, M. V., Robey, R., Bates, S., and Fojo, T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J. Clin. Invest., 105: 533-539, 2000.
26. Kennedy, M. J., Zahurak, M. L., Donehower, R. C., Noe, D., Grochow, L. B., Sartorius, S., Chen, T. L., Bowling, K., Duerr, M., and Rowinsky, E. K. Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet. Clin. Cancer Res., 4: 349-356, 1998.